The role of imaging in the clinical setting as well as in the drug development process is expanding rapidly. Imaging technology now exists that is capable of detecting tumor response within hours. In parallel with this advance, a new array of more targeted and specific therapies are being developed. This paradigm shift in turn demands a more sophisticated way of quantifying response. There is a need to update and modify the current response evaluation criteria in solid tumors (RECIST), which rely solely on anatomic size measurement of tumors. In addition, response assessment guidelines will need to be increasingly disease-specific. Response assessment by imaging is now intimately involved with all stages of the drug development process, from exploratory drug discovery through clinical trials, as well as in clinical use. Imaging biomarkers and surrogate endpoints have the potential to speed drug approval significantly. The major funding institutions and the pharmaceutical industry are working more and more with researchers to help maintain progress in this multidisciplinary area involving oncologists, radiologists, molecular imaging specialists, medical physicists, and computer scientists.

Author

S D Curran, A U Muellner and L H Schwartz

Contact Details

Corresponding address:
Lawrence H Schwartz, MD,
Department of Radiology,
Memorial Sloan-Kettering Cancer Center,
1275 York Avenue, New York, NY 10021, USA

Reference

ICIS Cancer Imaging Volume 6 Special Issue A
DOI: 10.1102/1470-7330.2006.9039

Date Posted

31 October 2006

Print PDF

Size

731.78 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	2 seconds
ADSL 512Kb/s (Broadband):	11 seconds
64 Kb/s (ISDN):	1 minute 31 seconds
33.3 Kb/s (Typical Modem):	2 minutes 55 seconds

Screen PDF

Size

264.38 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	4 seconds
64 Kb/s (ISDN):	33 seconds
33.3 Kb/s (Typical Modem):	1 minute 3 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.